Analyst Reports


 
    Bell Potter: Kazia Therapeutics - New In-license deal  
 
    Corporate Connect: Another Deal – Kazia Inlicences New Anti-Cancer Med From Highly Impressive Partner  
 
    H.C. Wainwright: Expanding Pipeline With EVT801 In-License; Reiterate Buy  
 
    Edison Research: New asset to target tumor lymphangiogenesis  
 
    Bell Potter: Kazia Therapeutics - China Out License Deal  
 
    Corporate Connect: Cantrixil licensed To Oasmia Pharmaceuticals & Kazia Shareholders Learn a Positive Lesson About Kazia  
 
    Edison Research: All in on GBM AGILE, but eyes on brain mets  
 
    HC Wainwright: A Unique PI3K Inhibitor for Brain Tumors; Initiate With Buy and $17 PT  
 
    Bell Potter: Kazia Therapeutics - Paxalisib Joins A Second Platform Study  
 
    Cantrixil final Phase I data reported (ADR update)  
 
    Edison Research: Cantrixil final Phase I data reported  
 
    Edison Research: Phase IIa shows good safety, consistent efficacy (ADR update)  
 
    Edison Research: Phase IIa shows good safety, consistent efficacy  
 
    Corporate Connect: Kazia Therapeutics - SNO Presentations: Late-Interim Results from Phase II GBM & Phase I DIPG Studies Released  
 
    Bell Potter: Kazia Therapeutics (KZA) - Results Unlikely Due To Chance  
 
    Bell Potter: Kazia Therapeutics - GBM Agile In More Detail  
 
    Corporate Connect: Kazia Therapeutics - A Laser-Like Focus on Adding Value - 5 Data Readouts in 9-Months  
 
    Bell Potter: Kazia Therapeutics - Approval Study Substantially Funded  
 
    Bell Potter: Kazia Therapeutics - Strength To Strength  
 
    Edison Research: Kazia Therapeutics - Bringing a vetted drug class to the brain  
 
    Bell Potter: Kazia Therapeutics - 5 month survival extension  
 
    Edison Research: Paxalisib trial still on track for H220 start  
 
    Edison Research: An agile pivot  
 
    Edison Research: An agile pivot (ADR Update)  
 
    Edison Research: GDC-0084 – encouraging initial efficacy (ADR Update)  
 
    Edison Research: GDC-0084 – encouraging initial efficacy  
 
    Edison Research - GDC-0084 gets a fifth collaboration  
 
    Edison Research - Higher MTD, new collaboration for GDC-0084  
 
    Edison Research: Higher MTD, new collaboration for GDC-0084 (ADR Outlook)  
 
    Edison Research: Cantrixil efficacy data presented at AACR (ADR Update)  
 
    Edison Research - Cantrixil efficacy data presented at AACR  
 
    Morgans interview with Kazia CEO Dr James Garner  
 
    Edison Research - New indications for GDC-0084  
 
    Edison Research: New indications for GDC-0084 (ADR Update)  
 
    Edison Research - GDC-0084 and Cantrixil trials progressing  
 
    Edison Research:GDC-0084 and Cantrixil trials progressing (ADR update)  
 
    Edison Research - GDC-0084 Phase II underway  
 
    Edison Research: GDC-0084 Phase II underway (ADR Outlook)  
 
    NDF Research Re-initiates Research Coverage on Kazia Therapeutics  
 
    Edison Research: GDC-0084 Phase II to begin shortly (ADR Update)  
 
    Cedrus Investments - Kazia Therapeutics Targeting Unmet Oncological Needs  
 
    NDF Research Initiates Research Coverage on Novogen  
 
    Edison Research: GDC-0084 Phase II on track to commence Q417 (ADR Update)  
 
    Edison Research - GDC-0084 Phase II on track to commence Q417  
 
    Edison Research: Anisina nixed, GDC-0084 on track for Phase II (ADR Outlook)  
 
    Edison research - Anisina nixed, GDC-0084 on track for Phase II  
 
    Edison research – Novogen Acquires Mid-Stage Cancer Drug from Genentech  
 
    H.C. Wainwright & Co Report – New Strategy in Place  
 
    Edison Research: Cantrixil to enter clinic in H216 (ADR Update)  
 
    Edison Report - Cantrixil to enter clinic in H216